What it does
Formed in 1997 as an investment syndicate, it now specialises in four areas – equity financing, debt financing, advisory services and fund management.
Braveheart invests in businesses through its many funds including the Finance Yorkshire Equity Fund, Strathclyde Innovation Fund and Lachesis Seed Fund.
The group, which floated on the London Stock Exchange in 2007, also invests on behalf of high net worth individuals, family offices, institutional investors and public sector organisations across the UK and Europe.
The company has about £71mln of funds under management with its portfolio spanning a number of sectors including healthcare equipment and services, travel and leisure, technology hardware and equipment, software and computer services, electronic and electrical equipment, and pharmaceuticals and biotechnology.
What it owns
Braveheart now holds six strategic investments in its portfolio alongside other historical investments.
These included biotechnology firm Kirkstall, UV light detection group Paraytec, propeller and rotating shaft monitoring group Gyrometric Systems, microscope imaging firm PhaseFocus and Sentinel Medical, a spin-out of Paraytec developing technology to detect cancer cells in urine.
On 8 July, the company said that it had also acquired a 33% stake in Pharm2Farm Limited (P2F), a plant nutrients firm, a stake it wants to increase to 54%.
In September, P2F announced a good result from a trial with Korean firm with a significant improvement in taste and the rate of growth of basil using its technology
What the boss says: Trevor Brown
"For the next year, our attention and resources will continue to be focussed upon the further development of the now six Strategic Investment businesses where we have significant commercial exposure. In each of these businesses there exists the prospect of a single transformational event, for example securing a large sales contract with a major OEM, the development of a new product or application and an outright sale to an acquirer."
Watch the video
In the first half of the current financial year, Braveheart made a profit before tax of £113,000 on revenue of £509,000. Net assets were worth 8.42p per share or £2.28mln.
Braveheart has announced its intention to take full 100% control of Paraytec through the issue of shares worth about £112,000.
At the first-half results, Braveheart said, “the investment portfolio, combined with substantial cash, continues to provide a solid underpinning to our balance sheet, and developments in our fund management business offer a new source of fund management revenue in the next financial year”.
With the shares trading around 1l.25p in September, Braveheart is valued at £3.1mln.